CP-012 has completed two clinical phase 1 studies, one in healthy volunteers and one in people with Parkinson's disease. Both used pharmacoscintigraphy, a technique that shows exactly when and where in the gut the tablet releases its content, combined with pharmacokinetics of carbidopa and levodopa.
CP-012 is an investigational product. It has not been approved by any regulatory authority, and its safety and efficacy have not been established.
Phase 1 studies of CP-012
"Contera address a true clinical need and an interesting formulation challenge. The collaboration is highly engaging and with a huge potential for the patients Contera works to help"
René Holm, Professor, Dr. Pham., SDU
Timing levodopa absorption to the early morning hours
Illustrative levodopa plasma profiles after bedtime dosing. Standard levodopa taken at bedtime is absorbed within the first hours and wears off during the night, so levels are low by the time patients wake up. CP-012 is designed to delay release, so that levodopa is absorbed in the early morning hours, before waking.
Phase 2
Proof-of-concept study
An International, randomised, double-blind, placebo-controlled study. The study will evaluate whether CP-012, taken at bedtime in addition to usual Parkinson’s medication, reduces early morning OFF episodes in people living with Parkinson’s disease. This is the first time the efficacy of CP-012 will be evaluated.